Back to the future: Recombinant polyclonal antibody therapeutics

Current Opinion in Chemical Engineering

Volumn 2, Issue 4, 2013, Pages 405-415

  Wang, Xian Zhe ^a   Coljee, Vincent W ^b   Maynard, Jennifer A ^c  

^a The University of Texas at Austin   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES;

ANTIBODY THERAPEUTICS; BINDING SPECIFICITIES; BOTULINUM TOXINS; CLINICAL EFFICACY; INFECTIOUS DISEASE; POLYCLONAL ANTIBODY; SINGLE MOLECULE; THROMBOCYTOPENIA;

ANTIBODIES;

EID: 84899980907     PISSN: None     EISSN: 22113398     Source Type: Journal    
DOI: 10.1016/j.coche.2013.08.005     Document Type: Review

References (86)

1. Reichert JM: Marketed therapeutic antibodies compendium. MAbs 2012, 4:413-415.
2. Wlaschin KF, Hu WS: Fedbatch culture and dynamic nutrient feeding. Adv Biochem Eng Biotechnol 2006, 101:43-74. (Pubitemid 44617165)
3. Maynard J, Georgiou G: Antibody engineering. Annu Rev Biomed Eng 2000, 2:339-376.
4. Fernandez P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group: A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr 2010, 10:38.
5. Stiehm ER, Keller MA, Vyas GN: Preparation and use of therapeutic antibodies primarily of human origin. Biologicals 2008, 36:363-374. (Pubitemid 50268032)
6. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J et al.: Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005, 79:9062-9068. (Pubitemid 40934817)
7. Demarest SJ, Hariharan K, Dong J: Emerging antibody combinations in oncology. MAbs 2011, 3:338-351.
8. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M: Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A 2009, 106:3294-3299.
9. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG et al.: Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008, 68: 4998-5003.
10. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES: Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002, 8:1720-1730. (Pubitemid 34633727)
11. Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004, 64:2343-2346. (Pubitemid 38523885)
12. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C et al.: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
13. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M: Sym004: a novel synergistic antiepidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010, 70:588-597.
14. Koefoed K, Steinaa L, Soderberg JN, Kjaer I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS et al.: Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011, 3:584-595.
15. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD: Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 2010, 107:13252-13257.
16. Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Jorgensen TK, Hey A, Kragh M: Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011, 17:5962-5972.
17. Volk WA, Bizzini B, Snyder RM, Bernhard E, Wagner RR: Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun 1984, 45:604-609. (Pubitemid 14066172)
18. de Kruif J, Kramer A, Visser T, Clements C, Nijhuis R, Cox F, van der Zande V, Smit R, Pinto D, Throsby M et al.: Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous V(H) genes. J Mol Biol 2009, 387:548-558.
19. Lang AB, Cryz SJ Jr, Schurch U, Ganss MT, Bruderer U: Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol 1993, 151:466-472.
20. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002, 99:11346-11350. (Pubitemid 34920928)
21. Cheng LW, Stanker LH, Henderson TD 2nd, Lou J, Marks JD: Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009, 77:4305-4313.
22. Tomic M, Garcia C, Lou J, Geren I, Meng Q, Conrad F, Wen W, Smith T, Brown J, Simpson L et al.: Recombinant monoclonal antibody based anti-toxin for treatment of type A, B, and E botulism. Public Health Emergency Medical Countermeasures Enterprise; Washington, DC: 2011.
23. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD: Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007, 25:107-116. (Pubitemid 46087909)
24. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ et al.: Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel 2011, 24:321-331.
25. Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, de Jong M, Jongeneelen M, Thijsse S, Backus HH et al.: The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 2005, 35:2131-2145. (Pubitemid 41015052)
26. Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, Rice AB, Kruif J, Dietzschold B, Bakker AB, Rupprecht CE: Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006, 193:796-801.
27. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, Lagerwerf F, Worst S, van Corven E, Kostense S et al.: First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922-5927.
28. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S et al.: Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
29. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E et al.: Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006, 3:e237.
30. Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keeffe EB, Matot E, Mizrachi S, Terkieltaub D, Zohar M et al.: Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology 2002, 35:673-679. (Pubitemid 34183973)
31. Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z et al.: Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006, 80:2654-2664. (Pubitemid 43346361)
32. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Koller U, Jilch R, Ammann CG, Pruenster M, Stoiber H, Katinger HW: Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004, 54:915-920. (Pubitemid 39529987)
33. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Gunthard HF: In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2008, 82:1591-1599.
34. Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, McKee K, Seaman MS, Bailer RT, Mascola JR: HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol 2012, 86:3393-3397.
35. Klitgaard JL, Coljee VW, Andersen PS, Rasmussen LK, Nielsen LS, Haurum JS, Bregenholt S: Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses. J Immunol 2006, 177:3782-3790. (Pubitemid 44359911)
36. Kumpel BM: Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007, 93:99-111. (Pubitemid 47228499)
37. Andersen PS, Haahr-Hansen M, Coljee VW, Hinnerfeldt FR, Varming K, Bregenholt S, Haurum JS: Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. Mol Immunol 2007, 44:412-422. (Pubitemid 44308352)
38. Godeau B, Oksenhendler E, Brossard Y, Bartholeyns J, Leaute JB, Duedari N, Schaeffer A, Bierling P: Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion 1996, 36:328-330. (Pubitemid 26141058)
39. Kjaersgaard M, Aslam R, Kim M, Speck ER, Freedman J, Stewart DI, Wiersma EJ, Semple JW: Epitope specificity and isotype of monoclonal anti-D antibodies dictate their ability to inhibit phagocytosis of opsonized platelets. Blood 2007, 110:1359-1361. (Pubitemid 47281437)
40. Robak T, Windyga J, Trelinski J, von Depka Prondzinski M, Giagounidis A, Doyen C, Janssens A, Alvarez-Roman MT, Jarque I, Loscertales J et al.: Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012, 120:3670-3676.
41. Lantto J, Haahr Hansen M, Rasmussen SK, Steinaa L, Poulsen TR, Duggan J, Dennis M, Naylor I, Easterbrook L, Bregenholt S et al.: Capturing the natural diversity of the human antibody response against vaccinia virus. J Virol 2011, 85:1820-1833.
42. Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H et al.: Passive immunotherapies protect WRvFire and IHD-JLuc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs. J Virol 2011, 85:9147-9158.
43. V.W. Coljee, Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof, US Patent 2010.
44. Zondervan Q, Carey K, Croal L, Dubey M, Porter J, Puro R, Reczek E, Russell H, Schneider R, Towle T et al.: Human recombinant antibody (Ab) cocktails protect against Methicillin Resistant Staphylococcus aureus (MRSA) infection in mice. Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA: 2010.
45. Bruss JB, Siber GR: Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin Diagn Lab Immunol 1999, 6:464-470. (Pubitemid 29330724)
46. Bruss JB, Malley R, Halperin S, Dobson S, Dhalla M, McIver J, Siber GR: Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr Infect Dis J 1999, 18:505-511. (Pubitemid 29277613)
47. Granstrom M, Olinder-Nielsen AM, Holmblad P, Mark A, Hanngren K: Specific immunoglobulin for treatment of whooping cough. Lancet 1991, 338:1230-1233.
48. Halperin SA, Vaudry W, Boucher FD, Mackintosh K, Waggener TB, Smith B: Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. Pediatr Infect Dis J 2007, 26:79-81. (Pubitemid 46045758)
49. Sato H, Sato Y: Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect Immun 1990, 58:3369-3374. (Pubitemid 20293448)
50. Sutherland JN, Maynard JA: Characterization of a key neutralizing epitope on pertussis toxin recognized by the monoclonal antibody 1B7. Biochemistry 2009, 48:11982-21199.
51. Lee SJ, Gray MC, Guo L, Sebo P, Hewlett EL: Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin. Infect Immun 1999, 67:2090-2100.
52. Maynard JA, Maassen CBM, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G: Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002, 20:597-601. (Pubitemid 34595154)
53. Binley JM, Ditzel HJ, Barbas CF 3rd, Sullivan N, Sodroski J, Parren PW, Burton DR: Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses 1996, 12:911-924. (Pubitemid 26230788)
54. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O et al.: Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008, 455:532-536.
55. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H: Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008, 329:112-124. (Pubitemid 350235462)
56. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 2009, 4:372-384.
57. Jiang N, He J, Weinstein JA, Penland L, Sasaki S, He XS, Dekker CL, Zheng NY, Huang M, Sullivan M et al.: Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med 2013, 5:ra119.
58. Cheung WC, Beausoleil SA, Zhang X, Sato S, Schieferl SM, Wieler JS, Beaudet JG, Ramenani RK, Popova L, Comb MJ et al.: A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat Biotechnol 2012, 30:447-452.
59. Wine Y, Boutz DR, Lavinder JJ, Miklos AE, Hughes RA, Hoi KH, Jung ST, Horton AP, Murrin EM, Ellington AD et al.: Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc Natl Acad Sci U S A 2013, 110:2993-2998.
60. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE Jr: Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol 2011, 187:3704-3711.
61. Poulsen TR, Jensen A, Haurum JS, Andersen PS: Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. J Immunol 2011, 187:4229-4235.
62. Poulsen TR, Meijer PJ, Jensen A, Nielsen LS, Andersen PS: Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J Immunol 2007, 179:3841-3850.
63. Foote J, Eisen HN: Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A 1995, 92:1254-1256.
64. Batista FD, Neuberger MS: Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 1998, 8:751-759. (Pubitemid 28294522)
65. Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW et al.: Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol 2006, 358:764-772.
66. Lauritsen KJ, Nguyen T: Combination products regulation at the FDA. Clin Pharmacol Ther 2009, 85:468-470.
67. Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R et al.: Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem 2012, 421:351-361.
68. Freeberg J, Li M, To R, Tomic R: Development of a lyophilized formulation for anti-BoNT A drug product XOMA 3AB. Interagency Botulism Research Coordinating Committee Meeting; Atlanta, GA: 2010.
69. Rasmussen SK, Nielsen LS, Muller C, Bouquin T, Naested H, Monster NT, Nygaard F, Weilguny D, Frandsen TP, Tolstrup AB: Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes. BMC Proc 2011, 5(Suppl 8):O2.
70. de Kruif J, Kramer A, Nijhuis R, van der Zande V, den Blanken R, Clements C, Visser T, Keehnen R, den Hartog M, Throsby M et al.: Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng 2010, 106:741-750.
71. Moran N: Mouse platforms jostle for slice of humanized antibody market. Nat Biotechnol 2013, 31:267-268.
72. Wiberg FC, Rasmussen SK, Frandsen TP, Rasmussen LK, Tengbjerg K, Coljee VW, Sharon J, Yang CY, Bregenholt S, Nielsen LS et al.: Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006, 94:396-405. (Pubitemid 43799538)
73. Persson P, Engstrom A, Rasmussen LK, Holmberg E, Frandsen TP: Development of mass spectrometry based techniques for the identification and determination of compositional variability in recombinant polyclonal antibody products. Anal Chem 2010, 82:7274-7282.
74. Frandsen TP, Naested H, Rasmussen SK, Hauptig P, Wiberg FC, Rasmussen LK, Jensen AM, Persson P, Wiken M, Engstrom A et al.: Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011, 108:2171-2181.
75. Nielsen LS, Baer A, Muller C, Gregersen K, Monster NT, Rasmussen SK, Weilguny D, Tolstrup AB: Single-batch production of recombinant human polyclonal antibodies. Mol Biotechnol 2010, 45:257-266.
76. Hicks SW, Wilmes GM, Lutz SR, Stevenson JA, Capacian MD, Carey KL, Colantonio AD, Russell HH, Reczek EE, Coljee VW: Non-viral adeno-associated virus-based platform for stable expression of polyclonal antibody mixtures and/or recombinant proteins. Immunology 2012, 137:658.
77. Read EK, Park JT, Brorson KA: Industry and regulatory experience of the glycosylation of monoclonal antibodies. Biotechnol Appl Biochem 2011, 58:213-219.
78. XTLbio: Annual Report. Valley Cottage, NY: 2006.
79. Cuker A: Are 25 antibodies better than 1? Blood 2012, 120:3627-3628.
80. Rasmussen SK, Naested H, Muller C, Tolstrup AB, Frandsen TP: Recombinant antibody mixtures: production strategies and cost considerations. Arch Biochem Biophys 2012, 526:139-145.
81. Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM et al.: Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011, 118:4053-4061.
82. Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, Qiang J, Meng T, Goutama M, Kwang J: Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS ONE 2009, 4:e 5672.
83. Chen Z, Moayeri M, Crown D, Emerson S, Gorshkova I, Schuck P, Leppla SH, Purcell RH: Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun 2009, 77:3902-3908.
84. Johan Lantto MWP, Jacobsen HJ, Poulsen TT, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID, Kragh M: Simultaneous inhibition of EGFR, HER2 and HER3 by an antibody mixture provides broad and potent tumor inhibition. Annual Meeting of the American Association for Cancer Research; Washington, DC: 2013.
85. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S et al.: Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013.
86. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Lifson JD et al.: Antibodymediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013.